Why Early-Stage Technical Risk Reduction is Crucial for Medical Device Startups: Interview with Diality CEO Osman Khawar

episode

Scott Nelson Live not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Scott Nelson Live

The Hidden Drivers of Clinical Trial Success: Interview with Rivermark CEO Dr. Adam Kadlec 57 min · 16 Dec 2025

Building the Market Before the Product: Interview with Inmedix CEO Andrew Holman, MD 52 min · 10 Dec 2025

All episodes from Scott Nelson Live →

Report any issue

Source

Recorded08 Mar 2023

Publisherfeeds.transistor.fm ↗

Handlerec:13866314

Show notes

In this episode of Medsider Radio, we sat down with Osman Khawar CEO of Diality.After obtaining an MD from the University of Glasgow and an MPH from Johns Hopkins, Osman Khawar went on to become a board-certified nephrologist with a passion for serving dialysis patients. As the CEO of Diality, he and his team are in the midst of creating a hemodialysis system that's versatile, mobile, intuitive, and cost-effective. In this interview, Osman discusses why early-stage technical risk reduction matters and how to navigate regulatory clearance through collaborative relationships. He also shares valuable tips on building and leading a mission-driven team. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's a link to the full interview with Osman if you'd rather read the summary instead.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.